Neuland Laboratories Limited reported annual results for the year ended 31 March 2026, with total income of Rs. 20,531 mn and EBITDA of Rs. 6,034 mn. The company said Q4FY26 revenue stood at Rs. 7,887 mn while Q4 EBITDA was Rs. 3,194 mn, reflecting strong sequential performance. Management noted robust operating leverage and improved margins during the fourth quarter.

EBITDA margin for Q4FY26 was 40.5 per cent, up from 17.3 per cent a year earlier, representing an increase of 2316 basis points. Profit before tax for the quarter was Rs. 2,870 mn and profit after tax was Rs. 2,125 mn. Year-on-year Q4 income rose 134.9 per cent while EBITDA increased 448.6 per cent and profit after tax grew 666.3 per cent.

The chief executive officer and managing director said the company had ended FY26 on a strong note and that business visibility was good in the short to medium term, anchored by commercial and near-commercial molecules. He said the company would focus on execution discipline, customer satisfaction and protection of business fundamentals while laying the groundwork for growth beyond the immediate horizon. Investments in peptide manufacturing and a new research and development centre were reported to be proceeding according to plan and business development efforts were being aligned to attract projects that support high quality, sustainable growth.

The company scheduled a one-hour earnings call at 17:30 IST on Tuesday, 12 May 2026, and said the transcript would be uploaded to the corporate website in due course. Neuland was described as a cGMP manufacturer with over four decades of experience, more than 300 developed processes, about 100 APIs and around 1000 regulatory filings across major jurisdictions, supported by multiple global certifications.